BRIEF published on 05/14/2024 at 22:20, 1 year 10 months ago NANOBIOTIX Launches Phase 2 Lung Cancer Treatment Study with FDA Approval FDA Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer
PRESS RELEASE published on 05/14/2024 at 22:15, 1 year 10 months ago NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer Nanobiotix announces US FDA protocol acceptance for new randomized Phase 2 study on NBTXR3 for stage three lung cancer patients Phase 2 Study NANOBIOTIX NBTXR3 Lung Cancer FDA Protocol
Published on 03/26/2026 at 16:20, 3 hours 31 minutes ago ACCESS Newswire Upgrades the ACCESS Platform to Include Social Monitoring to Track Brand Conversations Across Major Social Platforms
Published on 03/26/2026 at 13:00, 6 hours 51 minutes ago Prospect Ridge Strengthens Technical Team with Appointment of Phil Smerchanski as Senior Technical Advisor
Published on 03/26/2026 at 13:00, 6 hours 51 minutes ago GameSquare's Stream Hatchet Launches Creator Communities to Manage the Full Creator Marketing Lifecycle
Published on 03/26/2026 at 12:59, 6 hours 52 minutes ago Adcore Concludes Fiscal Year 2025 With Strong Q4 Performance
Published on 03/26/2026 at 19:20, 30 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 41 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:29, 1 hour 21 minutes ago IEVA GROUP: IEVA Group is listing on Euronext Growth® Paris to accelerate its growth and innovation strategy
Published on 03/26/2026 at 18:17, 1 hour 34 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 07:30, 12 hours 21 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
